vs
豪洛捷（HOLX）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是豪洛捷的2.0倍（$2.1B vs $1.0B），豪洛捷净利率更高（17.1% vs 15.8%，领先1.3%），Roper Technologies同比增速更快（11.3% vs 2.5%），Roper Technologies自由现金流更多（$507.0M vs $215.2M），过去两年Roper Technologies的营收复合增速更高（10.5% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
HOLX vs ROP — 直观对比
营收规模更大
ROP
是对方的2.0倍
$1.0B
营收增速更快
ROP
高出8.7%
2.5%
净利率更高
HOLX
高出1.3%
15.8%
自由现金流更多
ROP
多$291.8M
$215.2M
两年增速更快
ROP
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $2.1B |
| 净利润 | $179.1M | $331.0M |
| 毛利率 | 56.0% | 69.4% |
| 营业利润率 | 22.6% | 27.2% |
| 净利率 | 17.1% | 15.8% |
| 营收同比 | 2.5% | 11.3% |
| 净利润同比 | -10.9% | 842.6% |
| 每股收益（稀释后） | $0.79 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.0B | $2.1B | ||
| Q3 25 | $1.0B | $2.0B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.0B | $1.9B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.7B |
净利润HOLXROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $179.1M | $428.4M | ||
| Q3 25 | $187.2M | $398.5M | ||
| Q2 25 | $194.9M | $378.3M | ||
| Q1 25 | $-17.4M | $331.1M | ||
| Q4 24 | $201.0M | $462.3M | ||
| Q3 24 | $178.6M | $367.9M | ||
| Q2 24 | $194.5M | $337.1M |
毛利率HOLXROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 56.0% | 69.5% | ||
| Q3 25 | 55.6% | 69.5% | ||
| Q2 25 | 56.3% | 69.2% | ||
| Q1 25 | 37.5% | 68.7% | ||
| Q4 24 | 56.8% | 68.3% | ||
| Q3 24 | 56.4% | 69.2% | ||
| Q2 24 | 55.4% | 69.5% |
营业利润率HOLXROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | 22.6% | 28.6% | ||
| Q3 25 | 22.6% | 28.4% | ||
| Q2 25 | 24.9% | 28.2% | ||
| Q1 25 | -0.7% | 27.9% | ||
| Q4 24 | 22.5% | 28.0% | ||
| Q3 24 | 23.3% | 28.1% | ||
| Q2 24 | 24.1% | 28.8% |
净利率HOLXROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | 17.1% | 20.8% | ||
| Q3 25 | 17.8% | 19.8% | ||
| Q2 25 | 19.0% | 19.5% | ||
| Q1 25 | -1.7% | 17.6% | ||
| Q4 24 | 19.7% | 24.6% | ||
| Q3 24 | 18.1% | 20.8% | ||
| Q2 24 | 19.2% | 19.6% |
每股收益（稀释后）HOLXROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.79 | $3.97 | ||
| Q3 25 | $0.84 | $3.68 | ||
| Q2 25 | $0.86 | $3.49 | ||
| Q1 25 | $-0.08 | $3.06 | ||
| Q4 24 | $0.87 | $4.29 | ||
| Q3 24 | $0.75 | $3.40 | ||
| Q2 24 | $0.82 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $382.9M |
| 总债务越低越好 | $2.5B | $9.7B |
| 股东权益账面价值 | $5.2B | $18.8B |
| 总资产 | $9.2B | $34.6B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资HOLXROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $2.4B | $297.4M | ||
| Q3 25 | $2.2B | $320.0M | ||
| Q2 25 | $1.9B | $242.4M | ||
| Q1 25 | $1.6B | $372.8M | ||
| Q4 24 | $2.0B | $188.2M | ||
| Q3 24 | $2.3B | $269.6M | ||
| Q2 24 | $2.4B | $251.5M |
总债务HOLXROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $2.5B | $9.3B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $7.6B | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
股东权益HOLXROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $5.2B | $19.9B | ||
| Q3 25 | $5.0B | $20.0B | ||
| Q2 25 | $4.8B | $19.6B | ||
| Q1 25 | $4.6B | $19.2B | ||
| Q4 24 | $4.8B | $18.9B | ||
| Q3 24 | $5.1B | $18.5B | ||
| Q2 24 | $5.0B | $18.1B |
总资产HOLXROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $9.2B | $34.6B | ||
| Q3 25 | $9.0B | $34.6B | ||
| Q2 25 | $8.8B | $33.2B | ||
| Q1 25 | $8.5B | $31.4B | ||
| Q4 24 | $8.7B | $31.3B | ||
| Q3 24 | $9.2B | $31.6B | ||
| Q2 24 | $8.9B | $29.8B |
负债/权益比HOLXROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.48× | 0.47× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.40× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $507.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 24.2% |
| 资本支出强度资本支出/营收 | 1.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXROP
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $738.0M | ||
| Q3 25 | $355.1M | $869.5M | ||
| Q2 25 | $343.3M | $404.1M | ||
| Q1 25 | $169.4M | $528.7M | ||
| Q4 24 | $189.3M | $722.2M | ||
| Q3 24 | $367.0M | $755.4M | ||
| Q2 24 | $405.8M | $384.1M |
自由现金流HOLXROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — |
自由现金流率HOLXROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — |
资本支出强度HOLXROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — |
现金转化率HOLXROP
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.72× | ||
| Q3 25 | 1.90× | 2.18× | ||
| Q2 25 | 1.76× | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | 0.94× | 1.56× | ||
| Q3 24 | 2.05× | 2.05× | ||
| Q2 24 | 2.09× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
ROP
暂无分部数据
